Edwards Lifesciences (EW) Stock Forecast, Price & News

Edwards Lifesciences (NYSE:EW) Frequently Asked Questions

Is Edwards Lifesciences a buy right now?

23 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Edwards Lifesciences in the last year. There are currently 3 hold ratings and 20 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Edwards Lifesciences stock.
View analyst ratings for Edwards Lifesciences or view top-rated stocks.

Are investors shorting Edwards Lifesciences?

Edwards Lifesciences saw a decline in short interest in the month of April. As of April 30th, there was short interest totaling 4,860,000 shares, a decline of 15.2% from the April 15th total of 5,730,000 shares. Based on an average daily volume of 2,740,000 shares, the days-to-cover ratio is presently 1.8 days. Approximately 0.8% of the company's shares are sold short.
View Edwards Lifesciences' Short Interest.

When is Edwards Lifesciences' next earnings date?

Edwards Lifesciences is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for Edwards Lifesciences.

How were Edwards Lifesciences' earnings last quarter?

Edwards Lifesciences Co. (NYSE:EW) announced its quarterly earnings results on Tuesday, April, 26th. The medical research company reported $0.60 EPS for the quarter, beating the consensus estimate of $0.58 by $0.02. The medical research company earned $1.34 billion during the quarter, compared to the consensus estimate of $1.31 billion. Edwards Lifesciences had a trailing twelve-month return on equity of 25.80% and a net margin of 28.72%. The company's revenue for the quarter was up 10.2% on a year-over-year basis. During the same period last year, the firm earned $0.54 EPS.
View Edwards Lifesciences' earnings history.

When did Edwards Lifesciences' stock split? How did Edwards Lifesciences' stock split work?

Edwards Lifesciences's stock split before market open on Friday, May 29th 2020. The 3-1 split was announced on Thursday, May 7th 2020. The newly issued shares were issued to shareholders after the closing bell on Monday, May 18th 2020. An investor that had 100 shares of Edwards Lifesciences stock prior to the split would have 300 shares after the split.

What guidance has Edwards Lifesciences issued on next quarter's earnings?

Edwards Lifesciences issued an update on its FY22 earnings guidance on Tuesday, April, 26th. The company provided EPS guidance of $2.50-2.65 for the period, compared to the consensus EPS estimate of $2.56. The company issued revenue guidance of $5.5-6.0 billion, compared to the consensus revenue estimate of $5.76 billion.

What price target have analysts set for EW?

23 brokerages have issued 12-month target prices for Edwards Lifesciences' stock. Their forecasts range from $105.00 to $145.00. On average, they anticipate Edwards Lifesciences' stock price to reach $127.86 in the next year. This suggests a possible upside of 35.6% from the stock's current price.
View analysts' price targets for Edwards Lifesciences or view top-rated stocks among Wall Street analysts.

Who are Edwards Lifesciences' key executives?

Edwards Lifesciences' management team includes the following people:

• Mr. Michael A. Mussallem, Chairman & CEO (Age 69, Pay $2.88M)
• Mr. Scott B. Ullem, Corp. VP & CFO (Age 55, Pay $1.32M)
• Mr. Donald E. Bobo Jr., Corp. VP of Strategy & Corp. Devel. (Age 60, Pay $1.26M) (LinkedIn Profile)
• Mr. Larry L. Wood, Corp. VP of Transcatheter Aortic Valve Replacement (Age 56, Pay $1.31M) (LinkedIn Profile)
• Mr. Jean-Luc Lemercier, Corp. VP of Europe, Middle East, Africa, Canada & Latin America (Age 65, Pay $1.43M) (LinkedIn Profile)
• Dr. Todd J. Brinton, Corp. VP of Advanced Technology & Chief Scientific Officer
• Mark Wilterding, VP of Investor Relations
• Mr. Arnold A. Pinkston, Corp. VP & Gen. Counsel (Age 63)
• Mr. Dirksen J. Lehman, Corp. VP of Public Affairs
• Ms. Christine Z. McCauley, Corp. VP of HR (Age 57)

What is Michael A. Mussallem's approval rating as Edwards Lifesciences' CEO?

389 employees have rated Edwards Lifesciences CEO Michael A. Mussallem on Glassdoor.com. Michael A. Mussallem has an approval rating of 90% among Edwards Lifesciences' employees.

Who are some of Edwards Lifesciences' key competitors?

Some companies that are related to Edwards Lifesciences include Abbott Laboratories (ABT), Medtronic (MDT), Stryker (SYK), Intuitive Surgical (ISRG), Becton, Dickinson and (BDX), Boston Scientific (BSX), Baxter International (BAX), IDEXX Laboratories (IDXX), DexCom (DXCM), ResMed (RMD), STERIS (STE), Hologic (HOLX), Insulet (PODD), Teleflex (TFX) and Abiomed (ABMD).
View all of EW's competitors.

What other stocks do shareholders of Edwards Lifesciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Edwards Lifesciences investors own include NVIDIA (NVDA), Alibaba Group (BABA), Home Depot (HD), Salesforce (CRM), Walt Disney (DIS), Visa (V), Johnson & Johnson (JNJ), QUALCOMM (QCOM), Micron Technology (MU) and CVS Health (CVS).

What is Edwards Lifesciences' stock symbol?

Edwards Lifesciences trades on the New York Stock Exchange (NYSE) under the ticker symbol "EW."

Who are Edwards Lifesciences' major shareholders?

Edwards Lifesciences' stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (9.17%), Vanguard Group Inc. (8.00%), State Street Corp (4.33%), Capital International Investors (3.56%), Bank of New York Mellon Corp (3.51%) and Brown Advisory Inc. (2.67%). Company insiders that own Edwards Lifesciences stock include Catherine M Szyman, Catherine M Szyman, Donald E Bobo Jr, Heisz Leslie Stone, Huimin Wang, Jean-Luc M Lemercier, Kieran Gallahue, Larry L Wood, Martha H Marsh, Michael A Mussallem, Michael A Mussallem, Nicholas J Valeriani, Robert WA Sellers and Scott B Ullem.
View institutional ownership trends for Edwards Lifesciences.

Which institutional investors are selling Edwards Lifesciences stock?

EW stock was sold by a variety of institutional investors in the last quarter, including Sands Capital Management LLC, Capital Research Global Investors, Wellington Management Group LLP, Invesco Ltd., Sumitomo Mitsui Trust Holdings Inc., Canada Pension Plan Investment Board, Aviva PLC, and Royal Bank of Canada. Company insiders that have sold Edwards Lifesciences company stock in the last year include Catherine M Szyman, Donald E Bobo Jr, Huimin Wang, Jean-Luc M Lemercier, Kieran Gallahue, Larry L Wood, Martha H Marsh, and Michael A Mussallem.
View insider buying and selling activity for Edwards Lifesciences or view top insider-selling stocks.

Which institutional investors are buying Edwards Lifesciences stock?

EW stock was bought by a variety of institutional investors in the last quarter, including Vanguard Group Inc., CI Investments Inc., Stonehage Fleming Financial Services Holdings Ltd, Lord Abbett & CO. LLC, Swiss National Bank, Bridgewater Associates LP, Fisher Asset Management LLC, and Woodline Partners LP.
View insider buying and selling activity for Edwards Lifesciences or or view top insider-buying stocks.

How do I buy shares of Edwards Lifesciences?

Shares of EW can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Edwards Lifesciences' stock price today?

One share of EW stock can currently be purchased for approximately $94.32.

How much money does Edwards Lifesciences make?

Edwards Lifesciences has a market capitalization of $58.64 billion and generates $5.23 billion in revenue each year. The medical research company earns $1.50 billion in net income (profit) each year or $2.439990 on an earnings per share basis.

How many employees does Edwards Lifesciences have?

Edwards Lifesciences employs 15,700 workers across the globe.

Does Edwards Lifesciences have any subsidiaries?

The following companies are subsidiares of Edwards Lifesciences: BMEYE, CAS Medical Systems, CardiAQ Valve Technologies, Edwards Lifesciences (Japan) Limited, Edwards Lifesciences AG, Edwards Lifesciences Holding B.V., Edwards Lifesciences Innovation Holding LLC, Edwards Lifesciences LLC, Edwards Lifesciences Services GmbH, Embrella Cardiovascular, Harpoon Medical, Myocor, Percutaneous Valve Technologies, Valtech Cardio, and Whitland Research.

When was Edwards Lifesciences founded?

Edwards Lifesciences was founded in 1958.

What is Edwards Lifesciences' official website?

The official website for Edwards Lifesciences is www.edwards.com.

How can I contact Edwards Lifesciences?

Edwards Lifesciences' mailing address is ONE EDWARDS WAY, IRVINE CA, 92614. The medical research company can be reached via phone at (949) 250-2500, via email at [email protected], or via fax at 949-250-2525.